130 related articles for article (PubMed ID: 18568347)
1. Identification of novel tumor antigens with patient-derived immune-selected antibodies.
Rodriguez-Pinto D; Sparkowski J; Keough MP; Phoenix KN; Vumbaca F; Han DK; Gundelfinger ED; Beesley P; Claffey KP
Cancer Immunol Immunother; 2009 Feb; 58(2):221-34. PubMed ID: 18568347
[TBL] [Abstract][Full Text] [Related]
2. Antigen-driven oligoclonal expansion of tumor-infiltrating B cells in infiltrating ductal carcinoma of the breast.
Coronella JA; Spier C; Welch M; Trevor KT; Stopeck AT; Villar H; Hersh EM
J Immunol; 2002 Aug; 169(4):1829-36. PubMed ID: 12165506
[TBL] [Abstract][Full Text] [Related]
3. Identification of tumor-reactive B cells and systemic IgG in breast cancer based on clonal frequency in the sentinel lymph node.
McDaniel JR; Pero SC; Voss WN; Shukla GS; Sun Y; Schaetzle S; Lee CH; Horton AP; Harlow S; Gollihar J; Ellefson JW; Krag CC; Tanno Y; Sidiropoulos N; Georgiou G; Ippolito GC; Krag DN
Cancer Immunol Immunother; 2018 May; 67(5):729-738. PubMed ID: 29427082
[TBL] [Abstract][Full Text] [Related]
4. Identification of tumor-binding scFv derived from clonally related B cells in tumor and lymph node of a patient with breast cancer.
Novinger LJ; Ashikaga T; Krag DN
Cancer Immunol Immunother; 2015 Jan; 64(1):29-39. PubMed ID: 25261355
[TBL] [Abstract][Full Text] [Related]
5. Construction of phage display libraries from reactive lymph nodes of breast carcinoma patients and selection for specifically binding human single chain Fv on cell lines.
Rothe A; Klimka A; Tur MK; Pfitzner T; Huhn M; Sasse S; Mallmann P; Engert A; Barth S
Int J Mol Med; 2004 Oct; 14(4):729-35. PubMed ID: 15375609
[TBL] [Abstract][Full Text] [Related]
6. Antigen-driven clonal proliferation, somatic hypermutation, and selection of B lymphocytes infiltrating human ductal breast carcinomas.
Nzula S; Going JJ; Stott DI
Cancer Res; 2003 Jun; 63(12):3275-80. PubMed ID: 12810659
[TBL] [Abstract][Full Text] [Related]
7. Immunization with tumor neoantigens displayed on T7 phage nanoparticles elicits plasma antibody and vaccine-draining lymph node B cell responses.
Shukla GS; Sun YJ; Pero SC; Sholler GS; Krag DN
J Immunol Methods; 2018 Sep; 460():51-62. PubMed ID: 29906453
[TBL] [Abstract][Full Text] [Related]
8. RP215 single chain fragment variable and single domain recombinant antibodies induce cell cycle arrest at G0/G1 phase in breast cancer.
Yu F; Wang Y; Xiao Y; He Y; Luo C; Duan D; Li C; Xu S; Xiang T
Mol Immunol; 2014 May; 59(1):100-9. PubMed ID: 24534066
[TBL] [Abstract][Full Text] [Related]
9. Presence of breast cancer antigens in uninvolved axillary lymph nodes.
Hendler FJ; House D
Cancer Res; 1985 Jul; 45(7):3364-73. PubMed ID: 4005859
[TBL] [Abstract][Full Text] [Related]
10. Monoclonal antibody-defined phenotypes of regional lymph node and peripheral blood lymphocyte subpopulations in early breast cancer.
Morton BA; Ramey WG; Paderon H; Miller RE
Cancer Res; 1986 Apr; 46(4 Pt 2):2121-6. PubMed ID: 3081262
[TBL] [Abstract][Full Text] [Related]
11. Axillary lymph node cellular immune response to HER-2/neu peptides in patients with carcinoma of the breast.
Kuerer HM; Peoples GE; Sahin AA; Murray JL; Singletary SE; Castilleja A; Hunt KK; Gershenson DM; Ioannides CG
J Interferon Cytokine Res; 2002 May; 22(5):583-92. PubMed ID: 12060497
[TBL] [Abstract][Full Text] [Related]
12. Granzyme B production by activated B cells derived from breast cancer-draining lymph nodes.
Arabpour M; Rasolmali R; Talei AR; Mehdipour F; Ghaderi A
Mol Immunol; 2019 Oct; 114():172-178. PubMed ID: 31357083
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical evidence of immune responses to tumor-associated antigens in lymph nodes of colon carcinoma patients.
Mariani-Costantini R; Muraro R; Ficari F; Valli C; Bei R; Tonelli F; Caramia F; Frati L
Cancer; 1991 Jun; 67(11):2880-6. PubMed ID: 1709062
[TBL] [Abstract][Full Text] [Related]
14. The significance of cytokine-producing B cells in breast tumor-draining lymph nodes.
Mehdipour F; Razmkhah M; Faghih Z; Bagheri M; Talei AR; Ghaderi A
Cell Oncol (Dordr); 2019 Jun; 42(3):381-395. PubMed ID: 30850950
[TBL] [Abstract][Full Text] [Related]
15. A human monoclonal antibody to cytokeratin intermediate filament antigens derived from a tumor draining lymph node.
Skaletsky E; Oh E; Rulot C; Baird SM; Burnett KG; Masuho Y; Astarita RW; Haghighi P; Wolf P; Collins H
Hybridoma; 1988 Aug; 7(4):367-76. PubMed ID: 2459046
[TBL] [Abstract][Full Text] [Related]
16. Low mutation and neoantigen burden and fewer effector tumor infiltrating lymphocytes correlate with breast cancer metastasization to lymph nodes.
Wang Z; Liu W; Chen C; Yang X; Luo Y; Zhang B
Sci Rep; 2019 Jan; 9(1):253. PubMed ID: 30670769
[TBL] [Abstract][Full Text] [Related]
17. Localization of tumor-reactive lymph node lymphocytes in vivo using radiolabeled monoclonal antibody.
Triozzi PL; Kim JA; Aldrich W; Young DC; Sampsel JW; Martin EW
Cancer; 1994 Feb; 73(3):580-9. PubMed ID: 8299079
[TBL] [Abstract][Full Text] [Related]
18. Characterization of a monoclonal antibody that reacts with an activation antigen on human B cells: reactions on mitogen-stimulated blood lymphocytes and cells of normal lymph nodes.
Frisman D; Slovin S; Royston I; Baird S
Blood; 1983 Dec; 62(6):1224-9. PubMed ID: 6416334
[TBL] [Abstract][Full Text] [Related]
19. Identification and characterization of ErbB-3-binding protein-1 as a target for immunotherapy.
Santegoets SJ; Schreurs MW; Reurs AW; Lindenberg JJ; Kueter EW; van den Eertwegh AJ; Hooijberg E; Brandwijk RJ; Hufton SE; Hoogenboom HR; Scheper RJ; Somers VA; de Gruijl TD
J Immunol; 2007 Aug; 179(3):2005-12. PubMed ID: 17641068
[TBL] [Abstract][Full Text] [Related]
20. The balance of regulatory and stimulatory B cell subsets in breast cancer draining lymph nodes correlates with tumor prognostic factors.
Shariati S; Mehdipour F; Samadi M; Rasolmali R; Talei AR; Ghaderi A
Life Sci; 2020 Sep; 257():118117. PubMed ID: 32693243
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
